View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
October 13, 2016

Deals this week: Tepha, HTG Molecular Diagnostics, Midatech Pharma

Medical device company, Tepha, has entered a royalty obligations agreement with pharmaceutical company, Metabolix, to use the latter’s biopolymer technology in certain medical applications.

Medical device company, Tepha, has entered a royalty obligations agreement with pharmaceutical company, Metabolix, to use the latter’s biopolymer technology in certain medical applications.

As part of the agreement, which also includes two additional Metabolix production strains and related IP, Tepha will pay Metabolix $2m in order to avoid future royalties.

HTG Molecular Diagnostics and Merck KGaA have signed a broad companion diagnostics master agreement.

"Tepha will pay Metabolix $2m in order to avoid future royalties."

The initial development programme under the agreement involves using the former’s EdgeSeq DLBCL cell of origin assay in the latter’s development programme of M7583, a selective and irreversible inhibitor of Burton’s Tyrosine Kinase (BTK).

Midatech Pharma has raised £16m ($19.83m) through a private placement of its common stock shares, which was oversubscribed to by its existing and new investors.

The company has also raised £12m ($14.87m) in another private placement of its common stock shares.

The proceeds will be used by the company to expand and advance product development pipeline, to invest in its manufacturing and commercial platform and for working capital expenses.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU